Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer. (Q54631094)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer. (English)

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

1 reference

based on heuristic

inferred from title

author name string

Rohit Bhargava

1

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

David J Dabbs

2

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

Sushil Beriwal

3

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

Isil A Yildiz

4

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

Preeti Badve

5

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

Atilla Soran

6

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

Ronald R Johnson

7

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

Adam M Brufsky

8

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

Barry C Lembersky

9

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

Kandace P McGuire

10

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

Gretchen M Ahrendt

11

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

publication date

19 November 2010

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

Modern Pathology

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

24

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

3

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

367-374

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

https://scigraph.springernature.com/pub.10.1038/modpathol.2010.209

0 references

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Neoadjuvant therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Significance and problems in evaluations of pathological responses to neoadjuvant therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Crosstalk between IGF1R and estrogen receptor signaling in breast cancer.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

21 January 2018

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative (neoadjuvant) chemotherapy in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy for operable breast cancer: is this the future?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

7 January 2021

based on heuristic

inferred from DOI database lookup

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

7 January 2021

based on heuristic

inferred from DOI database lookup

Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

7 January 2021

based on heuristic

inferred from DOI database lookup

Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.209

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/MODPATHOL.2010.209

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

release_7fibqobx7zf6zpsuiobe4ugae4

1 reference

https://api.fatcat.wiki/v0/release/7fibqobx7zf6zpsuiobe4ugae4

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21102420

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54631094&oldid=1844625134"